There is a growing body of evidence to support NfL as a prognostic marker in early MS because it can predict MRI lesions, brain atrophy, and disability progression up to 10 years in advance (Table 2) [79–83, 85]. The gene discussed is NEFL; the disease is myeloid sarcoma.